FDA Approves Injectable Leqembi for Early Alzheimer's Disease Treatment
The FDA has approved Leqembi Iqlik, a new subcutaneous injectable for early Alzheimer's disease, offering a faster, more convenient treatment option for patients after initial IV therapy.
The U.S. Food and Drug Administration (FDA) has granted approval for Leqembi Iqlik, a new subcutaneous formulation of the Alzheimer’s medication lecanemab, designed for weekly administration following an initial 18-month intravenous (IV) treatment phase. This innovative autoinjector allows patients with early Alzheimer's disease, specifically in the mild cognitive impairment or mild dementia stages, to receive treatment in about 15 seconds. After completing the IV phase, patients can opt to continue with monthly infusions or switch to the convenient weekly subcutaneous injections.
This development aims to make Alzheimer's management more accessible and less burdensome. Howard Fillit, M.D., cofounder and chief science officer at the Alzheimer's Drug Discovery Foundation, highlighted that transitioning to subcutaneous dosing is a crucial step toward simplifying treatment, akin to diabetes medications like GLP-1 analogs. He emphasized that this innovation could eventually allow patients to administer therapy at home, bypassing the need for infusions.
The approval is based on data from the phase 3 Clarity AD extension trial, which demonstrated that patients switching to weekly Leqembi Iqlik maintained clinical and biomarker improvements comparable to those continuing IV therapy. The safety profile of the subcutaneous formulation was similar to IV dosing, with systemic reactions occurring in less than 1% of patients compared to about 26% with infusions. Amyloid-related imaging abnormalities (ARIA) were comparable between the two methods and aligned with rates seen in untreated patients.
Eisai and Biogen are the manufacturers of Leqembi Iqlik. This advancement is expected to improve patient comfort and adherence to therapy, supporting future combination treatments and enhancing overall management of early Alzheimer’s disease.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Health Insurers Commit to Enhancing Coverage Review Processes to Reduce Delays and Complaints
Major health insurers are pledging to reform coverage review processes, reducing delays and complaints, and standardizing prior authorization procedures to improve patient care and administrative efficiency.
Innovative Gene-Editing Platform Enhances Anti-Cancer Immunotherapy Safety and Effectiveness
A groundbreaking gene-editing platform enhances the safety and effectiveness of T cell–based cancer immunotherapies by enabling tumor-specific drug production, reducing side effects and boosting anti-cancer responses.
Lower Sleep Durations Increase Risks for Young Adults During Work and Driving
New research from Murdoch University reveals that multiple sleep disorders, insufficient sleep, and shift work significantly increase the risk of accidents among young adults, emphasizing the importance of comprehensive sleep health strategies.
Validation of AI Lung Cancer Risk Model in Black-Dominant Population Shows Promising Results
A new study validates the effectiveness of the AI-based Sybil lung cancer risk model in a racially diverse population, demonstrating high predictive accuracy and potential to improve early detection in underserved communities.